ArticleThe American journal of gastroenterology2018
Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study.
Article in The American journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06908785 (Utility of ROTEM® for Risk Stratification of Post-Invasive Procedure Hemorrhage in Patients With Cirrhosis), which is not on this map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Utility of ROTEM® for Risk Stratification of Post-Invasive Procedure Hemorrhage in Patients With Cirrhosis (CIR-ROTEM)
Who cites it
49 citing papers in PubMed.
- Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).Hepatology (Baltimore, Md.) · 2019Trial
- An Automated Microfluidic System for Haemostasis Assessment in Cirrhosis With Thrombocytopenia.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Balancing Thrombosis and Bleeding: Antithrombotic Therapy in Cirrhosis-Related Thrombocytopenia.Journal of clinical medicine · 2026Review
- Viscoelastic haemostatic assays in chronic liver disease-Profiling coagulation in the emergency department.Vox sanguinis · 2026Article
- Assessing primary hemostasis in cirrhosis: not only platelet count.Research and practice in thrombosis and haemostasis · 2026Article
- Coagulation Abnormalities in Liver Cirrhosis: Diagnostic and Therapeutic Approaches.Medicina (Kaunas, Lithuania) · 2026Review
- Beyond Rebalanced Haemostasis: Haemostatic Phenotypes, Thrombin Generation, and Clinical Risk in Chronic Liver Disease.TH open : companion journal to thrombosis and haemostasis · 2026Review
- Impact of Underlying Portal Hypertension on Severity and Course of Acute-On-Chronic Liver Failure.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Clinical Impact of Viscoelastic Testing in Liver Transplantation: A Before-and-After Study of Transfusion Needs and Outcomes.Journal of clinical medicine · 2025Article
- Construction and validation of a predictive model for the risk of rebleeding in patients with esophageal and gastric varices hemorrhage.BMC gastroenterology · 2024Article
- Relationship between platelet-to-lymphocyte ratio and early rebleeding after endoscopic variceal ligation: a bicenter retrospective study.Annals of medicine · 2024Article
- How to assess hemostasis in patients with severe liver disease.Hematology. American Society of Hematology. Education Program · 2023Article
- How to manage splanchnic vein thrombosis in patients with liver disease.Hematology. American Society of Hematology. Education Program · 2023Review
- How to manage hemostasis in patients with liver disease during interventions.Hematology. American Society of Hematology. Education Program · 2023Review
- [Risk factors and construction of a nomogram model for cirrhotic portal vein thrombosis combined with esophagogastric variceal bleeding].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Article
- Bleeding and Thrombosis in Patients With Cirrhosis: What's New?HemaSphere · 2023Article
- The impact of thrombocytopenia on variceal bleeding in cirrhotic patients with transjugular intrahepatic portosystemic shunt.Scientific reports · 2023Article
- Study protocol of Branch Atheromatous Disease-related stroke (BAD-study): a multicenter prospective cohort study.BMC neurology · 2022Article
- Thrombocytopenia and liver disease: pathophysiology and periprocedural management.Hematology. American Society of Hematology. Education Program · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThrombocytopenia is a hallmark for patients with cirrhosis and it is perceived as a risk factor for bleeding events. However, the relationship between platelet count and bleeding is still unclear.
methodsWe investigated the relationship between platelet count and major or clinical relevant nonmajor bleedings during a follow-up of ∼4 years.
resultsA total of 280 cirrhotic patients with different degrees of liver disease (67% males; age 64±37 years; 47% Child-Pugh B and C) were followed up for a median of 1,129 (interquartile range: 800-1,498) days yielding 953.12 patient-year of observation. The annual rate of any significant bleeding was 5.45%/year (3.57%/year and 1.89%/year for major and minor bleeding, respectively). Fifty-two (18.6%) patients experienced a major (n=34) or minor (n=18) bleeding event, predominantly from gastrointestinal origin. Platelet counts progressively decreased with the worsening of liver disease and were similar in patients with or without major or minor bleeding: a platelet count ≤50 × 10
conclusionsPlatelet count does not predict unprovoked major or minor bleeding in cirrhotic patients.
Indexed as
Identifiers
29257146What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.